Key result
Active cancer in acute PE is linked to ~451% greater 30-day mortality risk.
Why the study?
Patients with cancer-associated acute venous thromboembolism face high long-term risks of recurrence and bleeding, but the clinical features and short-term course across different cancer statuses required characterization.
Population
Adult patients with acute, symptomatic, objectively diagnosed PE (832 active cancer, 464 previous cancer, 3660 no cancer)
Comparison
Active cancer vs previous cancer vs no cancer
Design
Prospective, multicentre study
Follow-up
30 days
Authors
Loading...
Active cancer in acute PE signals higher 30-day death and bleeding risks; extends observational VTE data but leaves practice change open pending trials.
Cohort (n=4,956)
Yes
Hazard Ratio: 5.51 (95% CI 4.2–7.23)
Absolute Event Rate: 13.8% vs 2.6%
p-value: p=<0.0001
Patients with acute pulmonary embolism and active cancer have significantly higher 30-day mortality and major bleeding risks compared to those with previous or no cancer, with risks varying by cancer site.
Becattini et al. (2023) conducted a cohort in Acute pulmonary embolism (n=4,956). Active cancer vs. No cancer was evaluated on Death at 30 days (HR 5.51, 95% CI 4.20-7.23, p=<0.0001). Active cancer in patients with acute pulmonary embolism was associated with a significantly higher risk of death at 30 days compared to patients without cancer (13.8% vs 2.6%, HR 5.51).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: